Prof. Dr. med. Tobias Feuchtinger

Dr. von Haunersches Kinderspital, Klinikum der Universität München

Ludwig-Maximilians-Universität München
Lindwurmstrasse 4
D-80337 München
Phone: +49 89 4400-52759

University training and degree

1993 – 1999 Medical studies, Universities of Hamburg, Witten-Herdecke and Case Western Reserve University Cleveland/Ohio

Advanced academic qualifications

2009 Habilitation: “Adenovirus infection post SCT and adoptive T-cell therapy”, Tübingen University (Prof. R. Handgretinger)
Doctoral thesis: “Isolation of CD4+ dendritic cells and infect associated stimulation”, University Hospital Bochum, Laboratory of Immunology (Prof. U. Schauer)

Postgraduate professional career

2015 Full Professor of Pediatric Hematology/Oncology and head Department of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, LMU Munich
2009 – 2015
Attending physician Department of Pediatric Hematology/Oncology, Tübingen University
2005 – 2017
PI and board member CRC 685 “Immunotherapy: Molecular Basis and Clinical Application” (Speaker: H-G Rammensee), Tübingen University
2003 – 2015
Group leader & Qualified Person (GMP) Laboratory Immunotherapy, Tübingen University
2000 – 2009
Internship and Residency at University Children’s Hospital Tübingen
2002 – 2003
Postdoctoral research fellow, Stem Cell Laboratory at Tübingen University

Editorships, service on scientific advisory boards, awards etc.

a.) Articles published by outlets with scientific quality assurance, book publications and works accepted for publication, but not yet published

1) Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T. (2020). CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy. Blood. Epup ahead of print.

2) Willier S, Raedler J, Blaeschke F, Stenger D, Pazos Escudero M, Jurgeleit F, Grünewald TGP, Binder V, Schmid I, Albert MH, Wolf A, Feuchtinger T. (2020). Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells. Journal for ImmunoTherapy of Cancer. 8(2):e001052.

3) Kaeuferle T, Deisenberger L, Jablonowski L, Stief TA, Blaeschke F, Willier S, Feuchtinger T. (2020). CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation. Molecular Therapy. 11:S1525-0016(20)30292-6.

4) Stenger D, Stief TA, Käuferle T, Willier S, Rataj F, Schober K, Vick B, Lotfi R, Wagner B, Grünewald TGP, Kobold S, Busch DH, Jeremias I, Blaeschke F, Feuchtinger T. (2020). Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood. 136(12):1407-1418.

5) Blaeschke F, Willier S, Stenger D, Lepenies M, Horstmann MA, Escherich G, Zimmermann M, Rojas Ringeling F, Canzar S, Kaeuferle T, Rohlfs M, Binder V, Klein C, Feuchtinger T. (2020). Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. Leukemia. 34(10):2607-2620.

6) Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A, Schroeder C, Casadei N, Matthes J, Mohr C, Lotfi R, Wagner B, Kaeuferle T, Feucht J, Willier S, Handgretinger R, StevanoviĆ S, Lang P, Feuchtinger T. (2019) Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. Cytotherapy. 21(9):973-986.

7) Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T. (2018). Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunology Immunotherapy. 67(7):1053-1066.

8) Boekstegers AM, Blaeschke F, Schmid I, Wiebking V, Immler S, Hoffmann F, Bochmann K, Müller S, Grünewald TGP, Feucht J, Feuchtinger T. (2017). MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD. Bone Marrow Transplantaion. 52(8):1221-1224.

9) Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J, Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T. (2015). Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 19;125(12):1986-94.

10) Icheva, V., S. Kayser, D. Wolff, S. Tuve, C. Kyzirakos, W. Bethge, J. Greil, Albert, W. Schwinger, M. Nathrath, M. Schumm, S. Stevanovic, R. Handgretinger, P. Lang, T. Feuchtinger (2013). “Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.” J Clin Oncol. 1;31(1):39-48.